Impact of angiotensin II pathway inhibition on tumour response to anti PD(L)1 based therapy

Bookmark and Share
Published: 4 Nov 2020
Views: 86
Rating:
Save
Dr Julius Strauss - National Institutes of Health, Bethseda, USA

Dr Julius Strauss speaks to ecancer about the impact of angiotensin II pathway inhibition on tumour response to anti PD(L)1 based therapy at the virtual ENA 2020 meeting.

Initially, Dr Strauss explains the rationale behind this study and then moves on to explain the key results that were obtained. He then explains the methodology of this retrospective study and says that further research on this topic will be required to get a better about the impact of angiotensin II pathway inhibition on tumour response.

He talks about the type of cancers this pathway is more relevant to e.g; bladder cancer and winds it up, by telling what the impact of these results can be on precision medicine.